<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154672">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01852591</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-16727</org_study_id>
    <nct_id>NCT01852591</nct_id>
  </id_info>
  <brief_title>Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant</brief_title>
  <acronym>PCV13</acronym>
  <official_title>Exploration of Immune Response to Pneumococcal Conjugate Vaccine (PCV13) Administered Before and Early After Autologous Peripheral Stem Cell Transplant (Auto-PSCT) in Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is no study hypothesis.  The purpose of this study is to see if the Pneumococcal
      conjugate vaccine (PCV13), when administered before and early after an autologous peripheral
      stem cell transplant will induce an immune response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot study to determine the safety of PCV13 administered to patients with myeloma
      before and at +7-10 days and +21-24 days after autologous hematopoietic stem cell
      transplant; and,to quantify the immune response induced by PCV13 vaccination in patients
      with myeloma when administered before and early after autologous PSCT.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>180 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Efficacy based on immunologic response pre/post-vaccination.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>PCV 13</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pneumococcal conjugate vaccine (PCV13, 0.5ml) 3 to 30 days prior to transplant and then again at 7-10 and 21-24 days after transplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PCV13</intervention_name>
    <arm_group_label>PCV 13</arm_group_label>
    <other_name>Prevnar</other_name>
    <other_name>PCV13</other_name>
    <other_name>pneumococcal conjugate vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with confirmed multiple myeloma

          -  eligible for treatment with high dose melphalan based regimen and autologous
             peripheral stem cell transplant

        Exclusion Criteria:

          -  Pregnant or lactating woman, as evaluated by serum testing within 24 hours of
             administration of the first vaccine

          -  HIV infection confirmed by nucleic acid testing (NAT), as evaluated during pre
             transplant testing

          -  Common variable immunodeficiency or other inherited systemic immunodeficiency
             syndrome

          -  Active central nervous system (CNS) malignancy

          -  Prior malignancy within 5 years of enrollment excluding non-melanoma skin cancer or
             cervical carcinoma after curative resection, not requiring chemotherapy.

          -  History of severe allergy (e.g., anaphylaxis) to any component of pneumococcal
             conjugate vaccine 7 (PCV7), PCV13, or any diphtheria-toxoid containing vaccine.

          -  Inclusion on a separate trial in which patients may be randomized or otherwise
             started on maintenance chemotherapies within the first 3 months of autologous
             transplantation

          -  Patients with significant psychiatric illness likely to affect compliance, as
             determined by the treating physician

          -  Active or uncontrolled infection

          -  Diffusing lung capacity oxygenation (DLCO) &lt;50 %

          -  Left ventricular ejection fraction (LVEF) &lt;40%

          -  Bilirubin &gt;2
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederick L Locke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frederick Locke, MD</last_name>
    <phone>813-745-7202</phone>
    <email>Frederick.Locke@moffitt.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>H.Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederick L Locke, MD</last_name>
      <phone>813-745-7202</phone>
      <email>Frederick.Locke@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Melissa Alsina, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jongphil Kim, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bijal Shah, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudio Anasetti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Ochoa-Bayona, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Taiga Nishihori, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org</url>
    <description>H.Lee Moffitt Cancer Center &amp; Research Institute</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 6, 2014</lastchanged_date>
  <firstreceived_date>May 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>autologous transplant</keyword>
  <keyword>multiple myeloma</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
